2. Braze Inc. (NASDAQ:BRZE)
Braze soared by 19.87 percent on Wednesday to finish at $21.60 apiece, after the company posted an upbeat outlook for fiscal year 2027, saying that it expects to officially swing to profitability.
In an updated report, Braze Inc. (NASDAQ:BRZE) said that it is targeting a non-GAAP net income of $69 million to $73 million, or a reversal of its $130.8 million net loss in fiscal 2026.
Revenues are also targeted to grow by 19.8 to 20.5 percent year-on-year to a range of $884 million to $889 million, versus $738 million in the last fiscal period.
Last year, revenues surged by 24 percent from $593 million, primarily driven by new customers, upsells, and renewals.
In the last quarter of fiscal 2026, ending January, Braze Inc. (NASDAQ:BRZE) also widened its net loss by 85 percent to $31.58 million from $17.06 million in the same quarter a year earlier. Revenues, however, grew by 28 percent to $205.17 million from $160.4 million.
On the same day, Braze Inc. (NASDAQ:BRZE) announced plans to repurchase $100 million worth of its shares, $50 million of which are targeted for accelerated implementation.
“As we enter fiscal 2027, our financial profile is sound, and we are pleased that our strong balance sheet and consistent cash generation provide us with the flexibility to invest in our business while returning capital to shareholders. This authorization provides us with the flexibility to opportunistically return capital while maintaining the strong liquidity needed to pursue our ambitious roadmap for durable, profitable growth,” CFO Isabelle Winkles said.
“We are proud of the scale we have achieved and view this share repurchase program as a clear signal of our Board and management team’s confidence in our strategy, our market opportunity, and our ability to execute against our financial goals,” she added.
1. Sarepta Therapeutics Inc. (NASDAQ:SRPT)
Sarepta Therapeutics soared by 34.98 percent on Wednesday to finish at $23.77 apiece, as investors took path from Morgan Stanley’s 25-percent price target upgrade for its stock following strong clinical results from two of its rare disease drug candidates.
In a market note, Morgan Stanley raised its price target for Sarepta Therapeutics Inc. (NASDAQ:SRPT) to $25 from $20, while maintaining an “equal weight” rating for the stock.
The coverage followed the strong results of its SRP-1001 and SRP-1003, in treating patients with facioscapulohumeral muscular dystrophy (FSHD) and myotonic dystrophy type 1, respectively, with results showing a 90 percent reduction of the target protein or mRNA after a single dose, as compared with the 50 to 60 percent range from its competitors.
FSHD and DM1 are rare genetic diseases that are caused by othe verexpression of mutant proteins or toxic mRNA.
“We are pleased that these early clinical results showed high levels of siRNA delivery to muscle, with no saturation of muscle siRNA uptake or dose-limiting safety signals to date. We believe this supports the differentiated potential of this siRNA platform and strengthens our belief that this approach could meaningfully change the treatment landscape for patients with FSHD and DM1,” said Louise Rodino-Klapac, president of the research & development and technical Operations for Sarepta Therapeutics Inc. (NASDAQ:SRPT).
“These preliminary clinical data show consistent dose-dependent increases in plasma and muscle drug exposures across clinical and nonclinical studies and suggest that the αvβ6 integrin-targeting ligand mediates robust siRNA muscle delivery, which we hypothesize will ultimately enable higher dosing and translate into clinical efficacy for patients with FSHD1 and DM1,” she noted.
While we acknowledge the potential of SRPT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SRPT and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge fund investor letters by entering your email below.
